相关临床试验
13
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
23.1%
已完成
3
23.1%
尚未招募
1
7.7%
招募中
6
46.1%
暂无批准数据
- Novadip Biosciences has recruited the first pediatric patients for its pivotal phase 3 trial of NVD003, a tissue regenerative treatment for congenital pseudoarthrosis of the tibia (CPT). - The trial aims to enroll 12 children across eight sites in the EU and US by Q1 2026, with previous studies showing seven of eight CPT patients achieved durable bone union. - CPT affects less than 3.5 in 150,000 live births and often leads to multiple failed surgeries and potential limb amputation without effective treatment. - The company plans to launch an adult phase 3 trial in Q3 2026 for bone non-union, targeting market availability by 2027 for pediatric patients.
- Novadip Biosciences received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for NVD003, an autologous stem cell therapy for congenital pseudarthosis of the tibia (CPT). - Clinical data showed 88% of patients achieved fracture healing with NVD003, including children whose prior surgeries had failed. - The company plans to launch a pivotal phase 3 trial this month with recruitment in the US and Europe, targeting market entry by 2027. - NVD003 represents potential peak sales of $1.4 billion for large bone defects in pediatric and adult patients.
- Novadip Biosciences' NVDX3, an allogeneic bone grafting material derived from stem cells, demonstrated complete bone fracture union in all patients during a 12-month Phase Ib/IIa trial. - The first-in-human trial showed promising safety results with no treatment-related adverse events, paving the way for a planned Phase IIb/III trial in cervical spine fusion. - The breakthrough could address a significant unmet need in bone healing, particularly for patients with comorbidities who currently face up to 30% risk of non-union with existing treatments.
